Swiss pharma giant Roche (ROG: SIX) today released full-year 2024 financials, showing that group sales grew 7% at constant exchange rates (3% in francs) to 60.5 billion francs ($66.9 billion).
In 2024, core earnings rose by 7% at CER, and would have risen by 12% excluding the impact of the resolution of a tax dispute dating back to 2023.
Operating profit rose by 14% to 20.8 billion francs, slightly below the consensus target of 20.9 billion francs, driven by higher sales, improved gross margin and effective cost management.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze